Fertility and Sterility
Volume 82, Issue 1 , Pages 186-195 , July 2004

Hormonal factors and the risk of invasive ovarian cancer: a population-based case-control study

  • Malcolm C Pike, Ph.D.

      Affiliations

    • USC/Norris Comprehensive Cancer Center, Keck School of Medicine, Department of Preventive Medicine, University of Southern California, Los Angeles, California, USA
    • Corresponding Author InformationReprint requests: Malcolm C. Pike, Ph.D., USC/Norris Comprehensive Cancer Center, 1441 Eastlake Avenue, NOR4436, Los Angeles, California 90033, USA (FAX: 323-865-0125).
    • ,
  • Celeste L Pearce, Ph.D.

      Affiliations

    • USC/Norris Comprehensive Cancer Center, Keck School of Medicine, Department of Preventive Medicine, University of Southern California, Los Angeles, California, USA
    • ,
  • Ruth Peters, D.Sc.

      Affiliations

    • USC/Norris Comprehensive Cancer Center, Keck School of Medicine, Department of Preventive Medicine, University of Southern California, Los Angeles, California, USA
    • ,
  • Wendy Cozen, D.O.

      Affiliations

    • USC/Norris Comprehensive Cancer Center, Keck School of Medicine, Department of Preventive Medicine, University of Southern California, Los Angeles, California, USA
    • ,
  • Peggy Wan, M.S.

      Affiliations

    • USC/Norris Comprehensive Cancer Center, Keck School of Medicine, Department of Preventive Medicine, University of Southern California, Los Angeles, California, USA
    • ,
  • Anna H Wu, Ph.D.

      Affiliations

    • USC/Norris Comprehensive Cancer Center, Keck School of Medicine, Department of Preventive Medicine, University of Southern California, Los Angeles, California, USA

Received 23 September 2003 ,Revised 9 March 2004 ,Accepted 9 March 2004.

References 

  1. Fathalla MF. Factors in the causation and incidence of ovarian cancer. Obstet Gynecol Surv. 1972;27:751–768
  2. Dubeau L. The cell of origin of ovarian epithelial tumors and the ovarian surface epithelium dogma (does the emperor have no clothes?). Gynecol Oncol. 1999;72:437–442
  3. Newhouse ML, Pearson RM, Fullerton JM, Boesen EAM, Shannon HS. A case-control study of carcinoma of the ovary. Br J Prev Soc Med. 1977;31:148–153
  4. Casagrande JT, Pike MC, Ross RK, Louie EW, Roy S, Henderson BE. “Incessant ovulation” and ovarian cancer. Lancet. 1979;ii:170–173
  5. Cancer and Steroid Hormone Study (CASH) of the Centers for Disease Control and the National Institute of Child Health and Human Development . The reduction in the risk of ovarian cancer associated with oral contraceptive use. N Engl J Med. 1987;316:650–655
  6. Collaborative Ovarian Cancer Group Whittemore AS, Harris R, Itnyre J. Characteristics relating to ovarian cancer risk. Collaborative analysis of 12 US-case-control studies. II. Invasive epithelial ovarian cancers in white women. Am J Epidemiol. 1992;136:1184–1203
  7. Pike MC. Age-related factors in cancers of the breast, ovary, and endometrium. J Chron Dis. 1987;40:59S–69S
  8. Zhou H, Luo M, Schonthal AH, Pike MC, Stallcup MR, Zheng W, et al.  Influence of reproductive hormones on ovarian epithelial tumors (I. Effect on cell cycle activity). Cancer Biol. 2002;1:300–306
  9. Schildkraut JM, Calingaert B, Marchbanks PA, Moorman PG, Rodriguez GC. Impact of progestin and estrogen potency in oral contraceptives on ovarian cancer risk. J Natl Cancer Inst. 2002;94:32–38
  10. McCluskey LL, Dubeau L. Biology of ovarian cancer. Curr Opin Oncol. 1997;9:465–470
  11. Breslow NE, Day NE. Statistical methods in cancer research. Vol. 1. The analysis of case-control studies. Lyon, France: IARC, 1980. IARC Scientific Publication 32
  12. Henderson BE, Gordon RJ, Menck HR, SooHoo J, Martin SJ, Pike MC. Lung cancer and air pollution in south-central Los Angeles County. Am J Epidemiol. 1975;101:477–488
  13. Pike MC, Peters RK, Cozen W, Probst-Hensch NM, Felix JC, Wan PC, et al.  Estrogen-progestin replacement therapy and endometrial cancer. J Natl Cancer Inst. 1997;89:1110–1116
  14. Dickey RP, Stone SC. Progestational potency of oral contraceptives. Obstet Gynecol. 1976;47:106–112
  15. Purdie DM, Bain CJ, Webb PM, Whiteman DC, Pirozzo S, Green AC. Body size and ovarian cancer (case-control study and systematic review (Australia)). Cancer Causes Control. 2001;12:855–863
  16. Whiteman DC, Siskind V, Purdie DM, Green AC. Timing of pregnancy and the risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2003;12:42–46
  17. Titus-Ernstoff L, Perez K, Cramer DW, Harlow BL, Baron JA, Greenberg ER. Menstrual and reproductive factors in relation to ovarian cancer risk. Br J Cancer. 2001;84:714–721
  18. Risch HA, Marrett LD, Howe GR. Parity, contraception, infertility, and the risk of epithelial ovarian cancer. Am J Epidemiol. 1994;140:585–597
  19. Riman T, Dickman PW, Nilsson S, Correia N, Nordlinder H, Magnusson CM, et al.  Risk factors for invasive epithelial ovarian cancer (results from a Swedish case-control study). Am J Epidemiol. 2002;156:363–373
  20. Ness RB, Grisso JA, Klapper J, Schlesselman JJ, Silberzweig S, Vergona R, et al.  Risk of ovarian cancer in relation to estrogen and progestin dose and use characteristics of oral contraceptives. Am J Epidemiol. 2000;152:233–241
  21. Royar J, Becher H, Chang-Claude J. Low-dose oral contraceptives (protective effect on ovarian cancer risk). Int J Cancer. 2002;95:370–374
  22. Irwin KL, Weiss NS, Lee NC, Peterson HB. Tubal sterilization, hysterectomy, and the subsequent occurrence of epithelial ovarian cancer. Am J Epidemiol. 1991;134:362–369
  23. Hankinson SE, Hunter DJ, Colditz GA, Willett WC, Stampfer MJ, Rosner B, et al.  Tubal ligation, hysterectomy, and risk of ovarian cancer. J Am Med Assoc. 1993;270:2813–2818
  24. Green A, Purdie D, Bain C, Siskind V, Russell P, Quinn M, et al.  Tubal sterilisation, hysterectomy and decreased risk of ovarian cancer. Int J Cancer. 1997;71:948–951
  25. Schildkraut JM, Cooper GS, Halabi S, Calingaert B, Hartge P, Whittemore AS. Age at natural menopause and the risk of epithelial ovarian cancer. Obstet Gynecol. 2001;98:85–90
  26. Garg PP, Kerlikowske K, Subak L, Grady D. Hormone replacement therapy and the risk of epithelial ovarian carcinoma (a meta-analysis). Obstet Gynecol. 1998;92:472–479
  27. Coughlin SS, Giustozzi A, Smith SJ, Lee NC. A meta-analysis of estrogen replacement therapy and risk of epithelial ovarian cancer. J Clin Epidemiol. 2000;53:367–375
  28. Rodriguez C, Patel AV, Calle EE, Jacob EJ, Thun MJ. Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women. J Am Med Assoc. 2001;285:1460–1465
  29. Lacey JV, Mink PJ, Lubin JH, Sherman ME, Troisi R, Hartge P, et al.  Menopausal hormone replacement therapy and risk of ovarian cancer. J Am Med Assoc. 2002;288:334–341
  30. Riman T, Dickman PW, Nilsson S, Correia N, Nordliner H, Magnusson CM, et al.  Hormone replacement therapy and the risk of invasive epithelial ovarian cancer in Swedish women. J Natl Cancer Inst. 2002;94:497–504
  31. Weiss NS, Lyon JL, Krishnamurthy S, Dietert SE, Liff JM, Daling JR. Non-contraceptive estrogen use and the occurrence of ovarian cancer. J Natl Cancer Inst. 1982;68:95–98
  32. Cramer DW, Hutchison GB, Welch WR, Scully RE, Ryan KJ. Determinants of ovarian cancer risk. I. Reproductive experiences and family history. J Natl Cancer Inst. 1983;71:711–716
  33. Lee NC, Wingo PA, Peterson HB, Rubin GL, Sattin RW. Estrogen therapy and the risk of breast, ovarian and endometrial cancer. In: Mastroianni L Jr, Paulsen CA, eds. Aging, reproduction and the climacteric. New York: Plenum Press, 1986. pp. 287–303
  34. Risch HA. Estrogen replacement therapy and risk of epithelial ovarian cancer. Gynecol Oncol. 1996;63:254–257
  35. Purdie DM, Bain CJ, Siskind V, Russell P, Hacker NF, Ward BG, et al.  Hormone replacement therapy and risk of epithelial ovarian cancer. Br J Cancer. 1999;81:559–563
  36. Sit ASY, Modugno F, Weissfeld JL, Berga SL, Ness RB. Hormone replacement therapy formulations and risk of epithelial ovarian carcinoma. Gynecol Oncol. 2002;86:118–123
  37. Greenland S, Longnecker MP. Methods for trend estimation from summarized dose-response data, with applications to meta-analysis. Am J Epidemiol. 1992;135:1301–1309
  38. Kuper H, Cramer DW, Titus-Ernstoff L. Risk of ovarian cancer in the United States in relation to anthropometric measures (does the association depend on menopausal status?). Cancer Causes Control. 2002;13:455–463
  39. Lubin F, Chetrit A, Freedman LS, Alfandry E, Fisher Y, Nitzan H, et al.  Body mass index at age 18 years and during adult life and ovarian cancer risk. Am J Epidemiol. 2003;157:113–120
  40. Fairfield KM, Willett WC, Rosner BA, Manson JE, Speizer FE, Hankinson SE. Obesity, weight gain, and ovarian cancer. Obstet Gynecol. 2002;100:288–296
  41. Lukanova A, Toniolo P, Lundin E, Micheli A, Akhmedkhanov A, Biessy C, et al.  Body mass index in relation to ovarian cancer (a multi-centre nested case-control study). Int J Cancer. 2002;99:603–608
  42. Rodriguez C, Calle EE, Fakhrabadi-Shokoohi D, Jacobs EJ, Thun MJ. Body mass index, height, and the risk of ovarian cancer mortality in a prospective cohort of postmenopausal women. Cancer Epidemiol Biomarkers Prev. 2002;11:822–928
  43. Schouten LJ, Goldbohm RA, van den Brandt PA. Height, weight, weight change, and ovarian cancer risk in the Netherlands cohort study on diet and cancer. Am J Epidemiol. 2003;157:424–433
  44. Engeland A, Tretli S, Bjorge T. Height, body mass index, and ovarian cancer (a follow-up of 1.1 million Norwegian women). J Natl Cancer Inst. 2003;95:1244–1248
  45. Rodriguez GC, Walmer DK, Cline M, Krigman H, Lessey BA, Whitaker RS, et al.  Effect of progestin on the ovarian epithelium of macaques (cancer prevention through apoptosis?). J Soc Gynecol Invest. 1998;5:271–276
  46. Rodriguez GC, Nagarsheth NP, Lee KL, Bentley RC, Walmer DK, Cline M, et al.  Progestin-induced apoptosis in the Macaque ovarian epithelium (differential regulation of transforming growth factor-β). J Natl Cancer Inst. 2002;94:50–60

☆ Supported by Public Health Service (Bethesda, MD) grants CA 17054, CA 14089, CA 61132, and N01-PC-67010 (National Cancer Institute) and by subcontract 050-E8709 from the California Public Health Institute (Oakland, CA), which is supported by the California Department of Health Services as part of its statewide cancer reporting program mandated by Health and Safety Code Sections 210 and 211.3.

☆☆ The ideas and opinions expressed herein are those of the authors, and no endorsement by the State of California or the California Public Health Foundation is intended or should be inferred.

PII: S0015-0282(04)00556-4

doi: 10.1016/j.fertnstert.2004.03.013

Fertility and Sterility
Volume 82, Issue 1 , Pages 186-195 , July 2004

Article Tools